KSKush N. Shah

Kush N. Shah

*This is an algorithmically generated author record based on publicly available information.

Kush N. Shah has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hetero-Multivalent Targeted Liposomal Drug Delivery to Treat Pseudomonas aeruginosa Infections

    by Akshi Singla, Sabona B. Simbassa, Bhagath Chirra, Anirudh Gairola, Marie R. Southerland, Kush N. Shah, Robert E. Rose, Qingquan Chen, Ahmed Basharat, Jaime Baeza, et al.

    Pseudomonas aeruginosa is the leading nosocomial and community-acquired pathogen causing a plethora of acute and chronic infections. The Centers for Disease Control and Prevention has designated multidrug-resistant isolates of P. aeruginosa as a serious threat. A novel delivery vehicle capable of specifically targeting P. aeruginosa, and encapsulating antimicrobials, may address the challenges associated with these infections. We have developed hetero-multivalent targeted liposomes functionalized with host cell glycans to increase the delivery of antibiotics to the site of infection. Previously, we have demonstrated that compared with monovalent liposomes, these hetero-multivalent liposomes bind with higher affinity to P. aeruginosa. Here, compared with nontargeted liposomes, we have shown that greater numbers of targeted liposomes are found in the circulation, as well as at the site of P. aeruginosa (PAO1) infection in the thighs of CD-1 mice. No significant difference was found in the uptake of targeted, nontargeted, and PEGylated liposomes by J774.A1 macrophages. Ciprofloxacin-loaded liposomes were formulated and characterized for size, encapsulation, loading, and drug release. In vitro antimicrobial efficacy was assessed using CLSI broth microdilution assays and time-kill kinetics. Lastly, PAO1-inoculated mice treated with ciprofloxacin-loaded, hetero-multivalent targeted liposomes survived longer than mice treated with ciprofloxacin-loaded, monovalent targeted, or nontargeted liposomes and free ciprofloxacin. Thus, liposomes functionalized with host cell glycans target P. aeruginosa resulting in increased retention of the liposomes in the circulation, accumulation at the site of infection, and increased survival time in a mouse surgical site infection model. Consequently, this formulation strategy may improve outcomes in patients infected with P. aeruginosa.


  • Open Access

    Electrospun Antimicrobial, Anti‐Inflammatory, and Analgesic Bandages for Comprehensive Wound Treatment

    by Bhagath Chirra, Kush Shah, Morgan Chapman, Adel Hassan, Marie Southerland, Carolyn Cannon

    Chronic wounds affect more than 5 million Americans annually with an associated cost of $10 – 20 billion. These wounds provide perfect environments for bacterial growth, and are prone to infections, especially from multi‐drug resistant (MDR) pathogens. The current silver‐based bandages used to treat wounds exhibit a high toxicity toward fibroblasts, and lack anti‐inflammatory and analgesic activity. Our work focuses on the development of bandages to address these unmet clinical needs. We have fabricated electrospun polycaprolactone (PCL) scaffolds, capable of aiding in the wound healing process, and with incorporation of Ag + IBU, a novel therapeutic. These scaffolds deliver the drug locally at a controlled rate to impede bacterial infections. We have further functionalized PCL scaffolds with addition of polyethylene glycol (PEG) to accelerate drug release. Scanning electron microscopy images have revealed that our drug loaded scaffolds have a smooth fiber morphology and fiber diameter that is ~1 mm. Loading and release experiments were conducted by generating a standard curve for Ag + IBU using a Cytation 5 plate reader. Scaffolds loaded with either 5% or 10% Ag + IBU (w/w) release 40% of the drug within the first 24 hours. We have determined the antimicrobial efficacy of drug loaded scaffolds against planktonic and biofilm growth mode bacteria by measuring bacterial inhibition after incubation with scaffold for 24 hours. Microbiological assays have revealed that Ag + IBU‐loaded scaffolds are bactericidal against bacteria in both planktonic and biofilm growth mode. Cellular toxicity was determined against Human Dermal Fibroblasts using alamarBlue assay. Cytotoxicity assays have revealed that Ag + IBU‐loaded scaffolds exhibit toxicity toward human dermal fibroblasts at high concentrations. However, pre‐incubation with N‐acetyl cysteine (NAC), an antioxidant metabolite, abrogates this toxicity and significantly increases cell viability. We have fabricated two‐layer scaffolds with one layer rapidly delivering NAC and the second layer slowly releasing Ag + IBU. Compared with the commercially available bandages with antimicrobial properties currently used for wounds, our non‐toxic, antimicrobial, anti‐inflammatory, and analgesic scaffolds offer a more comprehensive treatment option.

  • Microstereolithography and characterization of poly(propylene fumarate)-based drug-loaded microneedle arrays

    by Yanfeng Lu, Satya Nymisha Mantha, Douglas C Crowder, Sofia Chinchilla, Kush N Shah, Yang H Yun, Ryan B Wicker, Jae-Won Choi

    Drug-loaded microneedle arrays for transdermal delivery of a chemotherapeutic drug were fabricated using multi-material microstereolithography ( μ SL). These arrays consisted of twenty-five poly(propylene fumarate) (PPF) microneedles, which were precisely orientated on the same polymeric substrate. To control the viscosity and improve the mechanical properties of the PPF, diethyl fumarate (DEF) was mixed with the polymer. Dacarbazine, which is widely used for skin cancer, was uniformly blended into the PPF/DEF solution prior to crosslinking. Each microneedle has a cylindrical base with a height of 700 μ m and a conical tip with a height of 300 μ m. Compression test results and characterization of the elastic moduli of the PPF/DEF (50:50) and PPF/drug mixtures indicated that the failure force was much larger than the theoretical skin insertion force. The release kinetics showed that dacarbazine can be released at a controlled rate for five weeks. The results demonstrated that the PPF-based drug-loaded microneedles are a potential method to treat skin carcinomas. In addition, μ SL is an attractive manufacturing technique for biomedical applications, especially for micron-scale manufacturing.


  • Open Access

    Phytochemicals potently inhibit migration of metastatic breast cancer cells

    by Stephanie Lemmo Ham, Samila Nasrollahi, Kush N. Shah, Andrew Soltisz, Sailaja Paruchuri, Yang H. Yun, Gary D. Luker, Anupam Bishayee, Hossein Tavana

    A high throughput screening technology enables identifying natural compounds, phytochemicals, that potently inhibit migration of metastatic breast cancer cells.


  • In Vivo Gene Delivery with l-Tyrosine Polyphosphate Nanoparticles

    by Andrew J. Ditto, John J. Reho, Kush N. Shah, Justin A. Smolen, James H. Holda, Rolando J. Ramirez, Yang H. Yun

    The concept of gene therapy is promising; however, the perceived risks and side effects associated with this technology have severely dampened the researchers’ enthusiasm.(1-3) Thus, the development of a nonviral gene vector without immunological effects and with high transfection efficiency is necessary. Currently, most nonviral vectors have failed to achieve the in vivo transfection efficiencies of viral vectors due to their toxicity,(4) rapid clearance,(5, 6) and/or inappropriate release rates.(7) Although our previous studies have successfully demonstrated the controlled-release of plasmid DNA (pDNA) polyplexes encapsulated into nanoparticles formulated with l-tyrosine polyphosphate (LTP-pDNA nanoparticles),(8, 9) the in vivo transfection capabilities and immunogenicity of this delivery system have yet to be examined. Thus, we evaluate LTP-pDNA nanoparticles in an in vivo setting via injection into rodent uterine tissue. Our results demonstrate through X-gal staining and immunohistochemistry of uterine tissue that transfection has successfully occurred after a nine-day incubation. In contrast, the results for the control nanoparticles show results similar to those of shams. Furthermore, reverse transcriptase polymerase chain reaction (RT-PCR) from the injected tissues confirms the transfection in vivo. To examine the immunogenicity, the l-tyrosine polyphosphate (LTP) nanoparticles have been evaluated in a mouse model. No significant differences in the activation of the innate immune system are observed. These data provide the first report for the potential use of controlled-release nanoparticles formulated from an amino acid based polymer as an in vivo nonviral vector for gene therapy.


  • The Interactions between l-Tyrosine Based Nanoparticles Decorated with Folic Acid and Cervical Cancer Cells under Physiological Flow

    by Andrew J. Ditto, Kush N. Shah, Nikki K. Robishaw, Matthew J. Panzner, Wiley J. Youngs, Yang H. Yun

    Many anticancer drugs have been established clinically, but their efficacy can be compromised by nonspecific toxicity and an inability to reach the desired cancerous intracellular spaces. In order to address these issues, researchers have explored the use of folic acid as a targeted moiety to increase specificity of chemotherapeutic drugs. To expand upon such research, we have conjugated folic acid to functionalized poly(ethylene glycol) and subsequently decorated the surface of l-tyrosine polyphosphate (LTP) nanoparticles. These nanoparticles possess the appropriate size (100–500 nm) for internalization as shown by scanning electron microscopy and dynamic light scattering. Under simulated physiological flow, LTP nanoparticles decorated with folic acid (targeted nanoparticles) show a 10-fold greater attachment to HeLa, a cervical cancer cell line, compared to control nanoparticles and to human dermal fibroblasts. The attachment of these targeted nanoparticles progresses at a linear rate, and the strength of this nanoparticle attachment is shown to withstand shear stresses of 3.0 dyn/cm2. These interactions of the targeted nanoparticles to HeLa are likely a result of a receptor–ligand binding, as a competition study with free folic acid inhibits the nanoparticle attachment. Finally, the targeted nanoparticles encapsulated with a silver based drug show increased efficacy in comparison to nondecorated (plain) nanoparticles and drug alone against HeLa cells. Thus, targeted nanoparticles are a promising delivery platform for developing anticancer therapies that overexpress the folate receptors (FRs).